Publications by authors named "K Yacisin"
Background: Respiratory Syncytial Virus (RSV) is an important pathogen causing acute respiratory illnesses in adults. RSV infection can lead to severe outcomes, including hospitalizations and even death. Despite the increased recognition of the burden in older adults, immediate post-discharge care needs among adults hospitalized with RSV are not well characterized and have not been compared to other serious medical conditions (such as influenza, acute myocardial infarction (MI), and stroke) for which there have been long-standing disease prevention efforts.
View Article and Find Full Text PDFAttributable Cost of Adult Respiratory Syncytial Virus Illness Beyond the Acute Phase.
Open Forum Infect Dis
March 2024
Background: Estimates of the cost of medically attended lower respiratory tract illness (LRTI) due to respiratory syncytial virus (RSV) in adults, especially beyond the acute phase, is limited. This study was undertaken to estimate the attributable costs of RSV-LRTI among US adults during, and up to 1 year after, the acute phase of illness.
Methods: A retrospective observational matched-cohort design and a US healthcare claims repository (2016-2019) were employed.
Introduction: While it is widely recognized that older adults, adults with chronic medical conditions (CMC), and adults with immunocompromising conditions (IC) are at increased risk of lower respiratory tract illness (LRTI), evidence of the magnitude of increased risk is limited. This study was thus undertaken to characterize rates of hospitalized and ambulatory LRTI among United States (US) adults by age and comorbidity profile.
Methods: A retrospective cohort design and US healthcare claims database (2016-2019) were employed.
Background: Older adults are at increased risk of adverse outcomes from pneumococcal disease and COVID-19. Vaccination is an established strategy for preventing both illnesses. This study evaluated the safety and immunogenicity of coadministration of the 20-valent pneumococcal conjugate vaccine (PCV20) and a booster (third dose) of BNT162b2 COVID-19 vaccine.
View Article and Find Full Text PDFArticle Synopsis
- Most RSV cases are diagnosed using nasal swabs, but testing other specimen types can improve detection rates significantly.
- A study containing 1766 patients showed that adding saliva, sputum, and serology tests resulted in a higher diagnosis rate of RSV compared to using nasal swabs alone.
- The combined testing led to a diagnosed rate increase from 3.2% to 6.2%, with sensitivities indicating that saliva, sputum, and serology are more effective than NP swabs alone.